#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
characterized. The most frequent chromosomal aberration is the loss of one
chromosome 18 in iNETs, however, the relevance of this alteration is unclear.